Around 80–90% of PCa cases are dependent on androgen at initial diagnosis; hence, androgen ablation therapy directed toward a reduction in serum androgens and the inhibition of androgen receptor (AR) is generally the first therapy adopted. The gene discussed is AR; the disease is posterior cortical atrophy.